Although type 2 diabetes treatment drugs for instance biguanides, α-glycosidase inhibitors, thiazolidinediones, sodium-dependent glucose transporter 2 (SGLT-2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists (Mehanna, 2013; Clapham, 2020) are gradually used in adjuvant treatment of T1DM (Warnes et al., 2018). This evidence concerns the gene DPP4 and type 1 diabetes mellitus.